摘要
[目的]探讨2013年ASCO/CAP指南对IHC2＋乳腺癌患者Her-2FISH分类的影响。[方法 ]采用荧光原位杂交法检测173例Her-2免疫组化2＋的乳腺癌患者的Her-2基因的状态并应用2013年ASCO/CAP指南的标准对检测结果进行分析。[结果]与2007年检测指南相比,使用2013年检测指南使36例患者发生了变化,取得了较高的阳性率（28.3%vs.23.1%）和不确定率（16.2%vs.4.0%）,阴性比例下降（55.5%vs.72.8%）。[结论 ]2013年指南的使用提高了阳性率和不确定患者的比例,从而提高了Her-2靶向治疗的病例数。FISH对于IHC2＋的患者能够起到最后分类的作用,而17号染色体多体在FISH不确定的患者中占很大的比例。
[Objective]To explore the ASCO/CAP guidelines for 2013 IHC2＋ Her-2 FISH breast cancer classification.[Methods]Using fluorescence in situ-hybridization method to detect 173 cases of Her-2 immunohistochemical 2＋ breast cancer patients in the state of the Her-2 gene ASCO/CAP guidelines of 2013 standard and applied to analyze test results.[Results]Compared with the testing guidelines in 2007,and 2013 were used to detect guidelines also resulted in the changes of 36 patients,the higher positive rate（28.3% vs.23.1%）and the uncertain rate（16.2%vs.4.0%）,negative percentage（55.5% vs.72.8%）.[Conclusion]2013 guidelines can improve the positive rate and the proportion of patients with uncertain,thus raise the number of cases of Her-2 targeted therapy,FISH for IHC2 ＋ patients can have the effect of the final classification,and polysomy 17 in FISH make up a large proportion of patients with uncertainty.
作者
刘思诗
陈可心
耿敬姝
LIU Si-shi;CHEN Ke-xin;GENG Jing-shu(The Affiliated Cancer Hospital of Harbin Medical University,Harbin 150081, China)
出处
《肿瘤学杂志》
CAS
2018年第3期203-207,共5页
Journal of Chinese Oncology
